1-Year Return on Invested Incremental Capital (1-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 1-year.
Teva Pharmaceutical Industries's 1-Year ROIIC % for the quarter that ended in Dec. 2023 was -66.65%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for Teva Pharmaceutical Industries's 1-Year ROIIC % or its related term are showing as below:
TEVA's 1-Year ROIIC % is ranked worse than 79.93% of 897
companies
in the Drug Manufacturers industry
Industry Median: 0.38
vs TEVA: -66.65
Teva Pharmaceutical Industries 1-Year ROIIC % Historical Data
The historical data trend for Teva Pharmaceutical Industries's 1-Year ROIIC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Teva Pharmaceutical Industries's 1-Year ROIIC %, along with its competitors' market caps and 1-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Teva Pharmaceutical Industries 1-Year ROIIC % Distribution
For the Drug Manufacturers industry and Healthcare sector, Teva Pharmaceutical Industries's 1-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where Teva Pharmaceutical Industries's 1-Year ROIIC % falls into.
Teva Pharmaceutical Industries's 1-Year ROIIC % for the quarter that ended in Dec. 2023 is calculated as:
1-Year ROIIC %
=
1-Year Incremental Net Operating Profit After Taxes (NOPAT)**
/
1-Year Incremental Invested Capital
=
( 3158.2272 (Dec. 2023) - 2143.123 (Dec. 2022) )
/
( 37868 (Dec. 2023) - 39391 (Dec. 2022) )
=
1015.1042
/
-1523
=
-66.65%***
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** TTM data of NOPAT and Invested Capital was used to calculate 1-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
Teva Pharmaceutical Industries 1-Year ROIIC % Related Terms
Thank you for viewing the detailed overview of Teva Pharmaceutical Industries's 1-Year ROIIC % provided by GuruFocus.com. Please click on the following links to see related term pages.
Teva Pharmaceutical Industries (Teva Pharmaceutical Industries) Business Description
Teva Pharmaceutical, based in Israel, is the leading generic drug manufacturer in the world. Teva derives half of its sales from North America and makes up a high-single-digit percentage of the total number of generic prescriptions in the U.S. It also has a significant presence in Europe, Japan, Russia, and Israel. Besides generics, Teva has a portfolio of innovative medicines and biosimilars in three main therapeutic areas: central nervous system with Copaxone, Ajovy and Austedo; respiratory with Qvar and ProAir; and oncology with Truxima, Herzuma, and Bendeka/Treanda. Teva also sells active pharmaceutical ingredients, offers contract manufacturing services, and owns Anda, a U.S.-based generic and specialty drug distributor.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
TEVA has been successfully added to your 